BIOMAT Database Logo BIOMAT Database Logo

Efficacy of pentavalent human-bovine (WC3) reassortant rotavirus vaccine based on breastfeeding frequency. 2008

Michelle G Goveia, and Mark J DiNubile, and Michael J Dallas, and Penny M Heaton, and Barbara J Kuter, and
From Merck & Co., Inc., West Point, PA, USA.

The efficacy of a live, oral, pentavalent rotavirus vaccine against G1-4 rotavirus gastroenteritis (RVGE) was retrospectively assessed based on breastfeeding frequency among 5098 infants in a placebo-controlled trial. The efficacy against any RVGE severity for infants never breastfed, sometimes breastfed, or exclusively breastfed was 68.3%, 82.2%, and 68.0%, respectively. The efficacy against severe RVGE was 100%, 95.4%, and 100%, respectively. Breastfeeding did not seem to adversely impact the efficacy of pentavalent rotavirus vaccine.

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D010919 Placebos Any dummy medication or treatment. Although placebos originally were medicinal preparations having no specific pharmacological activity against a targeted condition, the concept has been extended to include treatments or procedures, especially those administered to control groups in clinical trials in order to provide baseline measurements for the experimental protocol. Sham Treatment
D001942 Breast Feeding The nursing of an infant at the breast. Breast Fed,Breastfed,Milk Sharing,Wet Nursing,Breast Feeding, Exclusive,Breastfeeding,Breastfeeding, Exclusive,Exclusive Breast Feeding,Exclusive Breastfeeding,Sharing, Milk
D005759 Gastroenteritis INFLAMMATION of any segment of the GASTROINTESTINAL TRACT from ESOPHAGUS to RECTUM. Causes of gastroenteritis are many including genetic, infection, HYPERSENSITIVITY, drug effects, and CANCER. Gastroenteritides
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012189 Retrospective Studies Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons. Retrospective Study,Studies, Retrospective,Study, Retrospective
D012400 Rotavirus Infections Infection with any of the rotaviruses. Specific infections include human infantile diarrhea, neonatal calf diarrhea, and epidemic diarrhea of infant mice. Infection, Rotavirus,Infections, Rotavirus,Rotavirus Infection
D016865 Reassortant Viruses Viruses containing two or more pieces of nucleic acid (segmented genome) from different parents. Such viruses are produced in cells coinfected with different strains of a given virus. Reassortant Virus,Virus, Reassortant,Viruses, Reassortant
D022243 Rotavirus Vaccines Vaccines or candidate vaccines used to prevent infection with ROTAVIRUS. Rotavirus Vaccine,Vaccine, Rotavirus,Vaccines, Rotavirus

Related Publications

Michelle G Goveia, and Mark J DiNubile, and Michael J Dallas, and Penny M Heaton, and Barbara J Kuter, and
The integrated phase III safety profile of the pentavalent human-bovine (WC3) reassortant rotavirus vaccine.
November 2007, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases,
Michelle G Goveia, and Mark J DiNubile, and Michael J Dallas, and Penny M Heaton, and Barbara J Kuter, and
Molecular and biological characterization of the 5 human-bovine rotavirus (WC3)-based reassortant strains of the pentavalent rotavirus vaccine, RotaTeq.
August 2010, Virology,
Michelle G Goveia, and Mark J DiNubile, and Michael J Dallas, and Penny M Heaton, and Barbara J Kuter, and
Pentavalent human-bovine (WC3) reassortant rotavirus vaccine in special populations: a review of data from the Rotavirus Efficacy and Safety Trial.
July 2008, European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology,
Michelle G Goveia, and Mark J DiNubile, and Michael J Dallas, and Penny M Heaton, and Barbara J Kuter, and
Efficacy, immunogenicity, and safety of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine at the end of shelf life.
January 2007, Pediatrics,
Michelle G Goveia, and Mark J DiNubile, and Michael J Dallas, and Penny M Heaton, and Barbara J Kuter, and
Immunogenicity and safety of the pentavalent human-bovine (WC3) reassortant rotavirus vaccine (PRV) in Indian infants.
January 2013, Human vaccines & immunotherapeutics,
Michelle G Goveia, and Mark J DiNubile, and Michael J Dallas, and Penny M Heaton, and Barbara J Kuter, and
RotaTeq: a pentavalent bovine--human reassortant rotavirus vaccine.
January 2006, Pediatric annals,
Michelle G Goveia, and Mark J DiNubile, and Michael J Dallas, and Penny M Heaton, and Barbara J Kuter, and
Immunogenicity and safety of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine in healthy infants in Korea.
February 2008, The Pediatric infectious disease journal,
Michelle G Goveia, and Mark J DiNubile, and Michael J Dallas, and Penny M Heaton, and Barbara J Kuter, and
The new pentavalent rotavirus vaccine composed of bovine (strain WC3) -human rotavirus reassortants.
July 2006, The Pediatric infectious disease journal,
Michelle G Goveia, and Mark J DiNubile, and Michael J Dallas, and Penny M Heaton, and Barbara J Kuter, and
Robustness of the healthcare utilization results from the Rotavirus Efficacy and Safety Trial (REST) evaluating the human-bovine (WC3) reassortant pentavalent rotavirus vaccine (RV5).
June 2010, BMC pediatrics,
Michelle G Goveia, and Mark J DiNubile, and Michael J Dallas, and Penny M Heaton, and Barbara J Kuter, and
Efficacy of a pentavalent human-bovine reassortant rotavirus vaccine against rotavirus gastroenteritis among American Indian children.
February 2012, The Pediatric infectious disease journal,
Copied contents to your clipboard!